Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Vernon Holers to Animals

This is a "connection" page, showing publications Vernon Holers has written about Animals.

 
Connection Strength
 
 
 
2.035
 
  1. Holers VM. Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases. Immunobiology. 2025 May; 230(3):152915.
    View in: PubMed
    Score: 0.051
  2. Holers VM, Demoruelle KM, Buckner JH, James EA, Firestein GS, Robinson WH, Steere AC, Zhang F, Norris JM, Kuhn KA, Deane KD. Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis. Nat Rev Rheumatol. 2024 Oct; 20(10):601-613.
    View in: PubMed
    Score: 0.049
  3. Holers VM. Complement therapeutics are coming of age in rheumatology. Nat Rev Rheumatol. 2023 08; 19(8):470-485.
    View in: PubMed
    Score: 0.045
  4. Holers VM. Contributions of animal models to mechanistic understandings of antibody-dependent disease and roles of the amplification loop. Immunol Rev. 2023 01; 313(1):181-193.
    View in: PubMed
    Score: 0.043
  5. Banda NK, Tomlinson S, Scheinman RI, Ho N, Ramirez JR, Mehta G, Wang G, Vu VP, Simberg D, Kulik L, Holers VM. C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice. Front Immunol. 2020; 11:575154.
    View in: PubMed
    Score: 0.037
  6. Holers VM, Borodovsky A, Scheinman RI, Ho N, Ramirez JR, Dob? J, G?l P, Lindenberger J, Hansen AG, Desai D, Pihl R, Thiel S, Banda NK. Key Components of the Complement Lectin Pathway Are Not Only Required for the Development of Inflammatory Arthritis but Also Regulate the Transcription of Factor D. Front Immunol. 2020; 11:201.
    View in: PubMed
    Score: 0.036
  7. Kulik L, Laskowski J, Renner B, Woolaver R, Zhang L, Lyubchenko T, You Z, Thurman JM, Holers VM. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus. J Immunol. 2019 12 15; 203(12):3136-3147.
    View in: PubMed
    Score: 0.035
  8. Holers VM, Banda NK. Complement in the Initiation and Evolution of Rheumatoid Arthritis. Front Immunol. 2018; 9:1057.
    View in: PubMed
    Score: 0.032
  9. Antonioli AH, White J, Crawford F, Renner B, Marchbank KJ, Hannan JP, Thurman JM, Marrack P, Holers VM. Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins. J Immunol. 2018 01 01; 200(1):316-326.
    View in: PubMed
    Score: 0.031
  10. Banda NK, Acharya S, Scheinman RI, Mehta G, Takahashi M, Endo Y, Zhou W, Farrar CA, Sacks SH, Fujita T, Sekine H, Holers VM. Deconstructing the Lectin Pathway in the Pathogenesis of Experimental Inflammatory Arthritis: Essential Role of the Lectin Ficolin B and Mannose-Binding Protein-Associated Serine Protease 2. J Immunol. 2017 09 01; 199(5):1835-1845.
    View in: PubMed
    Score: 0.030
  11. Willis VC, Banda NK, Cordova KN, Chandra PE, Robinson WH, Cooper DC, Lugo D, Mehta G, Taylor S, Tak PP, Prinjha RK, Lewis HD, Holers VM. Protein arginine deiminase 4 inhibition is sufficient for the amelioration of collagen-induced arthritis. Clin Exp Immunol. 2017 05; 188(2):263-274.
    View in: PubMed
    Score: 0.029
  12. Banda NK, Acharya S, Scheinman RI, Mehta G, Coulombe M, Takahashi M, Sekine H, Thiel S, Fujita T, Holers VM. Mannan-Binding Lectin-Associated Serine Protease 1/3 Cleavage of Pro-Factor D into Factor D In Vivo and Attenuation of Collagen Antibody-Induced Arthritis through Their Targeted Inhibition by RNA Interference-Mediated Gene Silencing. J Immunol. 2016 11 01; 197(9):3680-3694.
    View in: PubMed
    Score: 0.028
  13. Holers VM, Tomlinson S, Kulik L, Atkinson C, Rohrer B, Banda N, Thurman JM. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol. 2016 06; 28(3):260-7.
    View in: PubMed
    Score: 0.028
  14. Holers VM. Targeting mechanisms at sites of complement activation for imaging and therapy. Immunobiology. 2016 06; 221(6):726-32.
    View in: PubMed
    Score: 0.026
  15. Kulik L, Hewitt FB, Willis VC, Rodriguez R, Tomlinson S, Holers VM. A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease. Mol Immunol. 2015 Feb; 63(2):479-88.
    View in: PubMed
    Score: 0.025
  16. Banda NK, Mehta G, Kjaer TR, Takahashi M, Schaack J, Morrison TE, Thiel S, Arend WP, Holers VM. Essential role for the lectin pathway in collagen antibody-induced arthritis revealed through use of adenovirus programming complement inhibitor MAp44 expression. J Immunol. 2014 Sep 01; 193(5):2455-68.
    View in: PubMed
    Score: 0.024
  17. Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014; 32:433-59.
    View in: PubMed
    Score: 0.023
  18. Holers VM. Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. Curr Opin Immunol. 2013 Dec; 25(6):728-35.
    View in: PubMed
    Score: 0.023
  19. Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, Mitchell LM, Hourcade DE, Hannan JP, Kovacs JM, Coughlin B, Woodell AS, Pickering MC, Rohrer B, Holers VM. Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest. 2013 May; 123(5):2218-30.
    View in: PubMed
    Score: 0.022
  20. Banda NK, Mehta G, Ferreira VP, Cortes C, Pickering MC, Pangburn MK, Arend WP, Holers VM. Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis. J Immunol. 2013 Apr 01; 190(7):3560-9.
    View in: PubMed
    Score: 0.022
  21. Cordova KN, Willis VC, Haskins K, Holers VM. A citrullinated fibrinogen-specific T cell line enhances autoimmune arthritis in a mouse model of rheumatoid arthritis. J Immunol. 2013 Feb 15; 190(4):1457-65.
    View in: PubMed
    Score: 0.022
  22. Holers VM, Rohrer B, Tomlinson S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol. 2013; 735:137-54.
    View in: PubMed
    Score: 0.022
  23. Asokan R, Banda NK, Szakonyi G, Chen XS, Holers VM. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol. 2013 Jan; 53(1-2):99-110.
    View in: PubMed
    Score: 0.021
  24. Thurman JM, Tchepeleva SN, Haas M, Panzer S, Boackle SA, Glogowska MJ, Quigg RJ, Holers VM. Complement alternative pathway activation in the autologous phase of nephrotoxic serum nephritis. Am J Physiol Renal Physiol. 2012 Jun 15; 302(12):F1529-36.
    View in: PubMed
    Score: 0.021
  25. Rohrer B, Coughlin B, Bandyopadhyay M, Holers VM. Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. J Ocul Pharmacol Ther. 2012 Aug; 28(4):402-9.
    View in: PubMed
    Score: 0.020
  26. Banda NK, Hyatt S, Antonioli AH, White JT, Glogowska M, Takahashi K, Merkel TJ, Stahl GL, Mueller-Ortiz S, Wetsel R, Arend WP, Holers VM. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol. 2012 Feb 01; 188(3):1469-78.
    View in: PubMed
    Score: 0.020
  27. Fridkis-Hareli M, Storek M, Mazsaroff I, Risitano AM, Lundberg AS, Horvath CJ, Holers VM. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood. 2011 Oct 27; 118(17):4705-13.
    View in: PubMed
    Score: 0.020
  28. Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y, Levitt B, Glogowska M, Chandra P, Kulik L, Robinson WH, Arend WP, Thompson PR, Holers VM. N-a-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol. 2011 Apr 01; 186(7):4396-404.
    View in: PubMed
    Score: 0.019
  29. Kulik L, Chen K, Huber BT, Holers VM. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists. Mol Immunol. 2011 Mar; 48(6-7):883-94.
    View in: PubMed
    Score: 0.019
  30. Rohrer B, Coughlin B, Kunchithapautham K, Long Q, Tomlinson S, Takahashi K, Holers VM. The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol Immunol. 2011 Mar; 48(6-7):e1-8.
    View in: PubMed
    Score: 0.019
  31. Banda NK, Takahashi M, Levitt B, Glogowska M, Nicholas J, Takahashi K, Stahl GL, Fujita T, Arend WP, Holers VM. Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis. J Immunol. 2010 Nov 01; 185(9):5598-606.
    View in: PubMed
    Score: 0.019
  32. Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am. 2010 May; 36(2):213-41.
    View in: PubMed
    Score: 0.018
  33. Rohrer B, Long Q, Coughlin B, Renner B, Huang Y, Kunchithapautham K, Ferreira VP, Pangburn MK, Gilkeson GS, Thurman JM, Tomlinson S, Holers VM. A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol. 2010; 703:137-49.
    View in: PubMed
    Score: 0.018
  34. Banda NK, Levitt B, Glogowska MJ, Thurman JM, Takahashi K, Stahl GL, Tomlinson S, Arend WP, Holers VM. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol. 2009 Nov 01; 183(9):5928-37.
    View in: PubMed
    Score: 0.017
  35. Kulik L, Fleming SD, Moratz C, Reuter JW, Novikov A, Chen K, Andrews KA, Markaryan A, Quigg RJ, Silverman GJ, Tsokos GC, Holers VM. Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury. J Immunol. 2009 May 01; 182(9):5363-73.
    View in: PubMed
    Score: 0.017
  36. Lyubchenko T, Nielsen JP, Miller SM, Liubchenko GA, Holers VM. Role of initial protein phosphorylation events and localized release-activated calcium influx in B cell antigen receptor signaling. J Leukoc Biol. 2009 Feb; 85(2):298-309.
    View in: PubMed
    Score: 0.016
  37. Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev. 2008 Jun; 223:300-16.
    View in: PubMed
    Score: 0.016
  38. Kuhn KA, Cozine CL, Tomooka B, Robinson WH, Holers VM. Complement receptor CR2/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collagen and citrullinated antigens. Mol Immunol. 2008 May; 45(10):2808-19.
    View in: PubMed
    Score: 0.016
  39. Holers VM. Antibodies to citrullinated proteins: pathogenic and diagnostic significance. Curr Rheumatol Rep. 2007 Oct; 9(5):396-400.
    View in: PubMed
    Score: 0.015
  40. Ho J, Moir S, Kulik L, Malaspina A, Donoghue ET, Miller NJ, Wang W, Chun TW, Fauci AS, Holers VM. Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J Immunol. 2007 Jun 01; 178(11):6968-74.
    View in: PubMed
    Score: 0.015
  41. Kulik L, Marchbank KJ, Lyubchenko T, Kuhn KA, Liubchenko GA, Haluszczak C, Gipson MG, Gibson MG, Boackle SA, Holers VM. Intrinsic B cell hypo-responsiveness in mice prematurely expressing human CR2/CD21 during B cell development. Eur J Immunol. 2007 Mar; 37(3):623-33.
    View in: PubMed
    Score: 0.014
  42. Thurman JM, Lenderink AM, Royer PA, Coleman KE, Zhou J, Lambris JD, Nemenoff RA, Quigg RJ, Holers VM. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol. 2007 Feb 01; 178(3):1819-28.
    View in: PubMed
    Score: 0.014
  43. Banda NK, Thurman JM, Kraus D, Wood A, Carroll MC, Arend WP, Holers VM. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol. 2006 Aug 01; 177(3):1904-12.
    View in: PubMed
    Score: 0.014
  44. Holers VM, Kulik L. Complement receptor 2, natural antibodies and innate immunity: Inter-relationships in B cell selection and activation. Mol Immunol. 2007 Jan; 44(1-3):64-72.
    View in: PubMed
    Score: 0.014
  45. Kraus DM, Elliott GS, Chute H, Horan T, Pfenninger KH, Sanford SD, Foster S, Scully S, Welcher AA, Holers VM. CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues. J Immunol. 2006 Apr 01; 176(7):4419-30.
    View in: PubMed
    Score: 0.014
  46. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, Holers VM. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest. 2006 Apr; 116(4):961-73.
    View in: PubMed
    Score: 0.014
  47. Thurman JM, Royer PA, Ljubanovic D, Dursun B, Lenderink AM, Edelstein CL, Holers VM. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J Am Soc Nephrol. 2006 Mar; 17(3):707-15.
    View in: PubMed
    Score: 0.013
  48. Thurman JM, Ljubanovic D, Royer PA, Kraus DM, Molina H, Barry NP, Proctor G, Levi M, Holers VM. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest. 2006 Feb; 116(2):357-68.
    View in: PubMed
    Score: 0.013
  49. Lyubchenko T, dal Porto J, Cambier JC, Holers VM. Coligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. J Immunol. 2005 Mar 15; 174(6):3264-72.
    View in: PubMed
    Score: 0.013
  50. Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell LM, Giclas PC, Salmon J, Gilkeson G, Holers VM. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol. 2005 Jan; 42(1):87-97.
    View in: PubMed
    Score: 0.012
  51. Carroll MC, Holers VM. Innate autoimmunity. Adv Immunol. 2005; 86:137-57.
    View in: PubMed
    Score: 0.012
  52. Holers VM. Complement receptors and the shaping of the natural antibody repertoire. Springer Semin Immunopathol. 2005 Mar; 26(4):405-23.
    View in: PubMed
    Score: 0.012
  53. Holers VM. Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus. J Clin Invest. 2004 Sep; 114(5):616-9.
    View in: PubMed
    Score: 0.012
  54. Holers VM, Thurman JM. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol Immunol. 2004 Jun; 41(2-3):147-52.
    View in: PubMed
    Score: 0.012
  55. Kang HJ, Bao L, Xu Y, Quigg RJ, Giclas PC, Holers VM. Increased serum C3 levels in Crry transgenic mice partially abrogates its complement inhibitory effects. Clin Exp Immunol. 2004 May; 136(2):194-9.
    View in: PubMed
    Score: 0.012
  56. Boackle SA, Culhane KK, Brown JM, Haas M, Bao L, Quigg RJ, Holers VM. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE. Autoimmunity. 2004 Mar; 37(2):111-23.
    View in: PubMed
    Score: 0.012
  57. Liu F, Ryan ST, Fahnoe KC, Morgan JG, Cheung AE, Storek MJ, Best A, Chen HA, Locatelli M, Xu S, Schmidt E, Schmidt-Jim?nez LF, Bieber K, Henderson JM, Lian CG, Verschoor A, Ludwig RJ, Benigni A, Remuzzi G, Salant DJ, Kalled SL, Thurman JM, Holers VM, Violette SM, Wawersik S. C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement. Mol Ther. 2024 Apr 03; 32(4):1061-1079.
    View in: PubMed
    Score: 0.012
  58. Holers VM, Boackle SA. Complement receptor 2 and autoimmunity. Curr Dir Autoimmun. 2004; 7:33-48.
    View in: PubMed
    Score: 0.012
  59. Whelan R, Feemster A, Laskowski J, Renner B, Kulik L, Poppelaars F, Lee C, Holers VM, Thurman JM. Female but Not Male Mice Deficient in Soluble IgM Are Susceptible to Chemically Induced Glomerular Injury. J Immunol. 2023 10 15; 211(8):1240-1248.
    View in: PubMed
    Score: 0.011
  60. Li Y, Jacques S, Gaikwad H, Wang G, Banda NK, Holers VM, Scheinman RI, Tomlinson S, Moghimi SM, Simberg D. Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins. Nat Nanotechnol. 2024 Feb; 19(2):246-254.
    View in: PubMed
    Score: 0.011
  61. Renner B, Poppelaars F, Laskowski J, Serkova NJ, Kulik L, Holers VM, Thurman JM. Noninvasive Detection of iC3b/C3d Deposits in the Kidney Using a Novel Bioluminescent Imaging Probe. J Am Soc Nephrol. 2023 07 01; 34(7):1151-1154.
    View in: PubMed
    Score: 0.011
  62. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003 Feb 01; 170(3):1517-23.
    View in: PubMed
    Score: 0.011
  63. Boackle SA, Holers VM. Role of complement in the development of autoimmunity. Curr Dir Autoimmun. 2003; 6:154-68.
    View in: PubMed
    Score: 0.011
  64. Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus. 2003; 12(7):535-8.
    View in: PubMed
    Score: 0.011
  65. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis. 2002 Nov; 61 Suppl 2:ii46-50.
    View in: PubMed
    Score: 0.011
  66. Hannan J, Young K, Szakonyi G, Overduin MJ, Perkins SJ, Chen X, Holers VM. Structure of complement receptor (CR) 2 and CR2-C3d complexes. Biochem Soc Trans. 2002 Nov; 30(Pt 6):983-9.
    View in: PubMed
    Score: 0.011
  67. Chriswell ME, Lefferts AR, Clay MR, Hsu AR, Seifert J, Feser ML, Rims C, Bloom MS, Bemis EA, Liu S, Maerz MD, Frank DN, Demoruelle MK, Deane KD, James EA, Buckner JH, Robinson WH, Holers VM, Kuhn KA. Clonal IgA and IgG autoantibodies from individuals at risk for rheumatoid arthritis identify an arthritogenic strain of Subdoligranulum. Sci Transl Med. 2022 10 26; 14(668):eabn5166.
    View in: PubMed
    Score: 0.011
  68. Marchbank KJ, Kulik L, Gipson MG, Morgan BP, Holers VM. Expression of human complement receptor type 2 (CD21) in mice during early B cell development results in a reduction in mature B cells and hypogammaglobulinemia. J Immunol. 2002 Oct 01; 169(7):3526-35.
    View in: PubMed
    Score: 0.011
  69. Renner B, Laskowski J, Poppelaars F, Ferreira VP, Blaine J, Antonioli AH, Hannan JP, Kovacs JM, van Kooten C, You Z, Pickering MC, Holers VM, Thurman JM. Factor H related proteins modulate complement activation on kidney cells. Kidney Int. 2022 12; 102(6):1331-1344.
    View in: PubMed
    Score: 0.011
  70. Fleming SD, Shea-Donohue T, Guthridge JM, Kulik L, Waldschmidt TJ, Gipson MG, Tsokos GC, Holers VM. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol. 2002 Aug 15; 169(4):2126-33.
    View in: PubMed
    Score: 0.011
  71. Schriek P, Ching AC, Moily NS, Moffat J, Beattie L, Steiner TM, Hosking LM, Thurman JM, Holers VM, Ishido S, Lahoud MH, Caminschi I, Heath WR, Mintern JD, Villadangos JA. Marginal zone B cells acquire dendritic cell functions by trogocytosis. Science. 2022 02 11; 375(6581):eabf7470.
    View in: PubMed
    Score: 0.010
  72. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002 Jan 21; 195(2):211-20.
    View in: PubMed
    Score: 0.010
  73. Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS, Malaspina A, Donoghue E, James JA, Lambris JD, Moir SA, Perkins SJ, Holers VM. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. J Immunol. 2001 Nov 15; 167(10):5758-66.
    View in: PubMed
    Score: 0.010
  74. Makar KW, Ulgiati D, Hagman J, Holers VM. A site in the complement receptor 2 (CR2/CD21) silencer is necessary for lineage specific transcriptional regulation. Int Immunol. 2001 May; 13(5):657-64.
    View in: PubMed
    Score: 0.010
  75. Takahashi K, Banda NK, Holers VM, Van Cott EM. Complement component factor B has thrombin-like activity. Biochem Biophys Res Commun. 2021 05 07; 552:17-22.
    View in: PubMed
    Score: 0.010
  76. Li C, Patel K, Tu Z, Yang X, Kulik L, Alawieh A, Allen P, Cheng Q, Wallace C, Kilkenny J, Kwon J, Gibney B, Cantu E, Sharma A, Pipkin M, Machuca T, Emtiazjoo A, Goddard M, Holers VM, Nadig S, Christie J, Tomlinson S, Atkinson C. A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 2021 06; 21(6):2067-2078.
    View in: PubMed
    Score: 0.010
  77. Marchbank KJ, Watson CC, Ritsema DF, Holers VM. Expression of human complement receptor 2 (CR2, CD21) in Cr2-/- mice restores humoral immune function. J Immunol. 2000 Sep 01; 165(5):2354-61.
    View in: PubMed
    Score: 0.009
  78. Holers VM. Phenotypes of complement knockouts. Immunopharmacology. 2000 Aug; 49(1-2):125-31.
    View in: PubMed
    Score: 0.009
  79. Song YJ, Choi IA, Meylan F, Demoruelle MK, Farley T, Richard AC, Hawley E, Botson J, Hong YJ, Lee EY, Mian SR, Hamilton BC, Thiele GM, Mikuls TR, Gara N, Ward CD, Lamberth S, Deane KD, Heller T, Ward MM, Lee DM, Migone TS, Stohl W, O'Dell JR, Norris JM, Holers VM, Gregersen P, Song YW, Siegel RM. Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF. Arthritis Res Ther. 2020 05 07; 22(1):106.
    View in: PubMed
    Score: 0.009
  80. Frid MG, McKeon BA, Thurman JM, Maron BA, Li M, Zhang H, Kumar S, Sullivan T, Laskowsky J, Fini MA, Hu S, Tuder RM, Gandjeva A, Wilkins MR, Rhodes CJ, Ghataorhe P, Leopold JA, Wang RS, Holers VM, Stenmark KR. Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. Am J Respir Crit Care Med. 2020 01 15; 201(2):224-239.
    View in: PubMed
    Score: 0.009
  81. Slight-Webb S, Bourn RL, Holers VM, James JA. Shared and unique immune alterations in pre-clinical autoimmunity. Curr Opin Immunol. 2019 12; 61:60-68.
    View in: PubMed
    Score: 0.009
  82. Hernandez G, Mills TS, Rabe JL, Chavez JS, Kuldanek S, Kirkpatrick G, Noetzli L, Jubair WK, Zanche M, Myers JR, Stevens BM, Fleenor CJ, Adane B, Dinarello CA, Ashton J, Jordan CT, Di Paola J, Hagman JR, Holers VM, Kuhn KA, Pietras EM. Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. Haematologica. 2020 03; 105(3):585-597.
    View in: PubMed
    Score: 0.008
  83. Gifford G, Vu VP, Banda NK, Holers VM, Wang G, Groman EV, Backos D, Scheinman R, Moghimi SM, Simberg D. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. J Control Release. 2019 05 28; 302:181-189.
    View in: PubMed
    Score: 0.008
  84. Nichols TC, Guthridge JM, Karp DR, Molina H, Fletcher DR, Holers VM. Gamma-glutamyl transpeptidase, an ecto-enzyme regulator of intracellular redox potential, is a component of TM4 signal transduction complexes. Eur J Immunol. 1998 12; 28(12):4123-9.
    View in: PubMed
    Score: 0.008
  85. Quigg RJ, He C, Lim A, Berthiaume D, Alexander JJ, Kraus D, Holers VM. Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med. 1998 Oct 05; 188(7):1321-31.
    View in: PubMed
    Score: 0.008
  86. Quigg RJ, Kozono Y, Berthiaume D, Lim A, Salant DJ, Weinfeld A, Griffin P, Kremmer E, Holers VM. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol. 1998 May 01; 160(9):4553-60.
    View in: PubMed
    Score: 0.008
  87. Okamoto T, Mathai SK, Hennessy CE, Hancock LA, Walts AD, Stefanski AL, Brown KK, Lynch DA, Cosgrove GP, Groshong SD, Cool CD, Schwarz MI, Banda NK, Thurman JM, Yang IV, Holers VM, Schwartz DA. The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2018 07 01; 315(1):L1-L10.
    View in: PubMed
    Score: 0.008
  88. Mihai S, Hirose M, Wang Y, Thurman JM, Holers VM, Morgan BP, K?hl J, Zillikens D, Ludwig RJ, Nimmerjahn F. Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice. Front Immunol. 2018; 9:535.
    View in: PubMed
    Score: 0.008
  89. Goetz L, Laskowski J, Renner B, Pickering MC, Kulik L, Klawitter J, Stites E, Christians U, van der Vlag J, Ravichandran K, Holers VM, Thurman JM. Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM. Eur J Immunol. 2018 05; 48(5):791-802.
    View in: PubMed
    Score: 0.008
  90. Kozono Y, Abe R, Kozono H, Kelly RG, Azuma T, Holers VM. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J Immunol. 1998 Feb 15; 160(4):1565-72.
    View in: PubMed
    Score: 0.008
  91. Makar KW, Pham CT, Dehoff MH, O'Connor SM, Jacobi SM, Holers VM. An intronic silencer regulates B lymphocyte cell- and stage-specific expression of the human complement receptor type 2 (CR2, CD21) gene. J Immunol. 1998 Feb 01; 160(3):1268-78.
    View in: PubMed
    Score: 0.008
  92. He YG, Pappworth IY, Rossbach A, Paulin J, Mavimba T, Hayes C, Kulik L, Holers VM, Knight AM, Marchbank KJ. A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice. Immunobiology. 2018 01; 223(1):125-134.
    View in: PubMed
    Score: 0.008
  93. Quigg RJ, Alexander JJ, Lo CF, Lim A, He C, Holers VM. Characterization of C3-binding proteins on mouse neutrophils and platelets. J Immunol. 1997 Sep 01; 159(5):2438-44.
    View in: PubMed
    Score: 0.008
  94. Takahashi K, Kozono Y, Waldschmidt TJ, Berthiaume D, Quigg RJ, Baron A, Holers VM. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol. 1997 Aug 01; 159(3):1557-69.
    View in: PubMed
    Score: 0.007
  95. Narang A, Qiao F, Atkinson C, Zhu H, Yang X, Kulik L, Holers VM, Tomlinson S. Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury , drive secondary injury by activating complement. J Neuroinflammation. 2017 06 19; 14(1):120.
    View in: PubMed
    Score: 0.007
  96. Kozono Y, Kotzin BL, Holers VM. Resting B cells from New Zealand Black mice demonstrate a defect in apoptosis induction following surface IgM ligation. J Immunol. 1996 Jun 01; 156(11):4498-503.
    View in: PubMed
    Score: 0.007
  97. Laskowski J, Renner B, Le Quintrec M, Panzer S, Hannan JP, Ljubanovic D, Ruseva MM, Borza DB, Antonioli AH, Pickering MC, Holers VM, Thurman JM. Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. Kidney Int. 2016 07; 90(1):109-22.
    View in: PubMed
    Score: 0.007
  98. Rich MC, Keene CN, Neher MD, Johnson K, Yu ZX, Ganivet A, Holers VM, Stahel PF. Site-targeted complement inhibition by a complement receptor 2-conjugated inhibitor (mTT30) ameliorates post-injury neuropathology in mouse brains. Neurosci Lett. 2016 Mar 23; 617:188-94.
    View in: PubMed
    Score: 0.007
  99. Renner B, Tong HH, Laskowski J, Jonscher K, Goetz L, Woolaver R, Hannan J, Li YX, Hourcade D, Pickering MC, Holers VM, Thurman JM. Annexin A2 Enhances Complement Activation by Inhibiting Factor H. J Immunol. 2016 Feb 01; 196(3):1355-65.
    View in: PubMed
    Score: 0.007
  100. Inturi S, Wang G, Chen F, Banda NK, Holers VM, Wu L, Moghimi SM, Simberg D. Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake. ACS Nano. 2015 Nov 24; 9(11):10758-68.
    View in: PubMed
    Score: 0.007
  101. Quigg RJ, Holers VM. Characterization of rat complement receptors and regulatory proteins. CR2 and Crry are conserved, and the C3b receptor of neutrophils and platelets is distinct from CR1. J Immunol. 1995 Aug 01; 155(3):1481-8.
    View in: PubMed
    Score: 0.006
  102. Molina H, Perkins SJ, Guthridge J, Gorka J, Kinoshita T, Holers VM. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules. J Immunol. 1995 May 15; 154(10):5426-35.
    View in: PubMed
    Score: 0.006
  103. Panzer SE, Laskowski J, Renner B, Kulik L, Ljubanovic D, Huber KM, Zhong W, Pickering MC, Holers VM, Thurman JM. IgM exacerbates glomerular disease progression in complement-induced glomerulopathy. Kidney Int. 2015 Sep; 88(3):528-37.
    View in: PubMed
    Score: 0.006
  104. Mehta G, Scheinman RI, Holers VM, Banda NK. A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA. J Immunol. 2015 Jun 01; 194(11):5446-54.
    View in: PubMed
    Score: 0.006
  105. Kozono Y, Duke RC, Schleicher MS, Holers VM. Co-ligation of mouse complement receptors 1 and 2 with surface IgM rescues splenic B cells and WEHI-231 cells from anti-surface IgM-induced apoptosis. Eur J Immunol. 1995 Apr; 25(4):1013-7.
    View in: PubMed
    Score: 0.006
  106. Atkinson C, Qiao F, Yang X, Zhu P, Reaves N, Kulik L, Goddard M, Holers VM, Tomlinson S. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
    View in: PubMed
    Score: 0.006
  107. Kim YU, Kinoshita T, Molina H, Hourcade D, Seya T, Wagner LM, Holers VM. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med. 1995 Jan 01; 181(1):151-9.
    View in: PubMed
    Score: 0.006
  108. Molina H, Kinoshita T, Webster CB, Holers VM. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2. J Immunol. 1994 Jul 15; 153(2):789-95.
    View in: PubMed
    Score: 0.006
  109. Neher MD, Rich MC, Keene CN, Weckbach S, Bolden AL, Losacco JT, Patane J, Flierl MA, Kulik L, Holers VM, Stahel PF. Deficiency of complement receptors CR2/CR1 in Cr2?/? mice reduces the extent of secondary brain damage after closed head injury. J Neuroinflammation. 2014 May 24; 11:95.
    View in: PubMed
    Score: 0.006
  110. Holers VM, Hollis GF, Schwartz BD, Evans RJ, Strauss-Schoenberger J, Carel JC, Barney DL, Li B, Stafford-Hollis J, Lacy PE. Induction of peri-insulitis but not diabetes in islet transplants expressing a single foreign antigen. A multi-stage model of disease. J Immunol. 1993 Nov 01; 151(9):5041-52.
    View in: PubMed
    Score: 0.006
  111. Li B, Sallee C, Dehoff M, Foley S, Molina H, Holers VM. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol. 1993 Oct 15; 151(8):4295-305.
    View in: PubMed
    Score: 0.006
  112. Foley S, Li B, Dehoff M, Molina H, Holers VM. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation. Eur J Immunol. 1993 Jun; 23(6):1381-4.
    View in: PubMed
    Score: 0.006
  113. Keith RC, Sokolove J, Edelman BL, Lahey L, Redente EF, Holers VM, Sakaguchi S, Robinson WH, Riches DW. Testosterone is protective in the sexually dimorphic development of arthritis and lung disease in SKG mice. Arthritis Rheum. 2013 Jun; 65(6):1487-93.
    View in: PubMed
    Score: 0.006
  114. Arend WP, Mehta G, Antonioli AH, Takahashi M, Takahashi K, Stahl GL, Holers VM, Banda NK. Roles of adipocytes and fibroblasts in activation of the alternative pathway of complement in inflammatory arthritis in mice. J Immunol. 2013 Jun 15; 190(12):6423-33.
    View in: PubMed
    Score: 0.006
  115. Joseph K, Kulik L, Coughlin B, Kunchithapautham K, Bandyopadhyay M, Thiel S, Thielens NM, Holers VM, Rohrer B. Oxidative stress sensitizes retinal pigmented epithelial (RPE) cells to complement-mediated injury in a natural antibody-, lectin pathway-, and phospholipid epitope-dependent manner. J Biol Chem. 2013 May 03; 288(18):12753-65.
    View in: PubMed
    Score: 0.006
  116. Strassheim D, Renner B, Panzer S, Fuquay R, Kulik L, Ljubanovic D, Holers VM, Thurman JM. IgM contributes to glomerular injury in FSGS. J Am Soc Nephrol. 2013 Feb; 24(3):393-406.
    View in: PubMed
    Score: 0.005
  117. Hu X, Holers VM, Thurman JM, Schoeb TR, Ramos TN, Barnum SR. Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE. Mol Immunol. 2013 Jul; 54(3-4):302-8.
    View in: PubMed
    Score: 0.005
  118. Holers VM, Kinoshita T, Molina H. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol Today. 1992 Jun; 13(6):231-6.
    View in: PubMed
    Score: 0.005
  119. Weckbach S, Neher M, Losacco JT, Bolden AL, Kulik L, Flierl MA, Bell SE, Holers VM, Stahel PF. Challenging the role of adaptive immunity in neurotrauma: Rag1(-/-) mice lacking mature B and T cells do not show neuroprotection after closed head injury. J Neurotrauma. 2012 Apr 10; 29(6):1233-42.
    View in: PubMed
    Score: 0.005
  120. Li K, Gor J, Holers VM, Storek MJ, Perkins SJ. Solution structure of TT30, a novel complement therapeutic agent, provides insight into its joint binding to complement C3b and C3d. J Mol Biol. 2012 May 04; 418(3-4):248-63.
    View in: PubMed
    Score: 0.005
  121. Liubchenko GA, Appleberry HC, Holers VM, Banda NK, Willis VC, Lyubchenko T. Potentially autoreactive naturally occurring transitional T3 B lymphocytes exhibit a unique signaling profile. J Autoimmun. 2012 Jun; 38(4):293-303.
    View in: PubMed
    Score: 0.005
  122. Krych M, Atkinson JP, Holers VM. Complement receptors. Curr Opin Immunol. 1992 Feb; 4(1):8-13.
    View in: PubMed
    Score: 0.005
  123. Molina H, Wong W, Kinoshita T, Brenner C, Foley S, Holers VM. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med. 1992 Jan 01; 175(1):121-9.
    View in: PubMed
    Score: 0.005
  124. Elvington A, Atkinson C, Kulik L, Zhu H, Yu J, Kindy MS, Holers VM, Tomlinson S. Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol. 2012 Feb 01; 188(3):1460-8.
    View in: PubMed
    Score: 0.005
  125. Keith RC, Powers JL, Redente EF, Sergew A, Martin RJ, Gizinski A, Holers VM, Sakaguchi S, Riches DW. A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice. Exp Lung Res. 2012 Mar; 38(2):55-66.
    View in: PubMed
    Score: 0.005
  126. Takeda K, Thurman JM, Tomlinson S, Okamoto M, Shiraishi Y, Ferreira VP, Cortes C, Pangburn MK, Holers VM, Gelfand EW. The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness and inflammation. J Immunol. 2012 Jan 15; 188(2):661-7.
    View in: PubMed
    Score: 0.005
  127. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, Crish JF, Bebek G, Ritter SY, Lindstrom TM, Hwang I, Wong HH, Punzi L, Encarnacion A, Shamloo M, Goodman SB, Wyss-Coray T, Goldring SR, Banda NK, Thurman JM, Gobezie R, Crow MK, Holers VM, Lee DM, Robinson WH. Identification of a central role for complement in osteoarthritis. Nat Med. 2011 Nov 06; 17(12):1674-9.
    View in: PubMed
    Score: 0.005
  128. Khan MA, Jiang X, Dhillon G, Beilke J, Holers VM, Atkinson C, Tomlinson S, Nicolls MR. CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res. 2011 Nov 11; 109(11):1290-301.
    View in: PubMed
    Score: 0.005
  129. Banda NK, Takahashi M, Takahashi K, Stahl GL, Hyatt S, Glogowska M, Wiles TA, Endo Y, Fujita T, Holers VM, Arend WP. Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement. Mol Immunol. 2011 Oct; 49(1-2):281-9.
    View in: PubMed
    Score: 0.005
  130. Molina H, Brenner C, Jacobi S, Gorka J, Carel JC, Kinoshita T, Holers VM. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction. J Biol Chem. 1991 Jul 05; 266(19):12173-9.
    View in: PubMed
    Score: 0.005
  131. Pappworth IY, Hayes C, Dimmick J, Morgan BP, Holers VM, Marchbank KJ. Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression. Immunobiology. 2012 Feb; 217(2):147-57.
    View in: PubMed
    Score: 0.005
  132. Renner B, Ferreira VP, Cortes C, Goldberg R, Ljubanovic D, Pangburn MK, Pickering MC, Tomlinson S, Holland-Neidermyer A, Strassheim D, Holers VM, Thurman JM. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int. 2011 Jul; 80(2):165-73.
    View in: PubMed
    Score: 0.005
  133. Molina H, Kinoshita T, Inoue K, Carel JC, Holers VM. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol. 1990 Nov 01; 145(9):2974-83.
    View in: PubMed
    Score: 0.005
  134. Shaw CD, Storek MJ, Young KA, Kovacs JM, Thurman JM, Holers VM, Hannan JP. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking. J Mol Biol. 2010 Dec 10; 404(4):697-710.
    View in: PubMed
    Score: 0.005
  135. Renner B, Strassheim D, Amura CR, Kulik L, Ljubanovic D, Glogowska MJ, Takahashi K, Carroll MC, Holers VM, Thurman JM. B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J Immunol. 2010 Oct 01; 185(7):4393-400.
    View in: PubMed
    Score: 0.005
  136. Renner B, Coleman K, Goldberg R, Amura C, Holland-Neidermyer A, Pierce K, Orth HN, Molina H, Ferreira VP, Cortes C, Pangburn MK, Holers VM, Thurman JM. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol. 2010 Sep 01; 185(5):3086-94.
    View in: PubMed
    Score: 0.005
  137. Carel JC, Myones BL, Frazier B, Holers VM. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem. 1990 Jul 25; 265(21):12293-9.
    View in: PubMed
    Score: 0.005
  138. Serkova NJ, Renner B, Larsen BA, Stoldt CR, Hasebroock KM, Bradshaw-Pierce EL, Holers VM, Thurman JM. Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology. 2010 May; 255(2):517-26.
    View in: PubMed
    Score: 0.004
  139. Thurman JM, Renner B, Kunchithapautham K, Holers VM, Rohrer B. Aseptic injury to epithelial cells alters cell surface complement regulation in a tissue specific fashion. Adv Exp Med Biol. 2010; 664:151-8.
    View in: PubMed
    Score: 0.004
  140. Banda NK, Levitt B, Wood AK, Takahashi K, Stahl GL, Holers VM, Arend WP. Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro. Clin Exp Immunol. 2010 Jan; 159(1):100-8.
    View in: PubMed
    Score: 0.004
  141. Carel JC, Frazier B, Ley TJ, Holers VM. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells. J Immunol. 1989 Aug 01; 143(3):923-30.
    View in: PubMed
    Score: 0.004
  142. Holers VM, Ruff TG, Parks DL, McDonald JA, Ballard LL, Brown EJ. Molecular cloning of a murine fibronectin receptor and its expression during inflammation. Expression of VLA-5 is increased in activated peritoneal macrophages in a manner discordant from major histocompatibility complex class II. J Exp Med. 1989 May 01; 169(5):1589-605.
    View in: PubMed
    Score: 0.004
  143. Twohig JP, Pappworth IY, Sivasankar B, Kulik L, Bull M, Holers VM, Wang EC, Marchbank KJ. Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice. Mol Immunol. 2009 Jun; 46(10):2002-13.
    View in: PubMed
    Score: 0.004
  144. Pappworth IY, Kulik L, Haluszczak C, Reuter JW, Holers VM, Marchbank KJ. Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21). Mol Immunol. 2009 Mar; 46(6):1042-9.
    View in: PubMed
    Score: 0.004
  145. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008 Dec 01; 181(11):8068-76.
    View in: PubMed
    Score: 0.004
  146. Banda NK, Wood AK, Takahashi K, Levitt B, Rudd PM, Royle L, Abrahams JL, Stahl GL, Holers VM, Arend WP. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum. 2008 Oct; 58(10):3081-9.
    View in: PubMed
    Score: 0.004
  147. Clark A, Weymann A, Hartman E, Turmelle Y, Carroll M, Thurman JM, Holers VM, Hourcade DE, Rudnick DA. Evidence for non-traditional activation of complement factor C3 during murine liver regeneration. Mol Immunol. 2008 Jun; 45(11):3125-32.
    View in: PubMed
    Score: 0.004
  148. Zaiss AK, Cotter MJ, White LR, Clark SA, Wong NC, Holers VM, Bartlett JS, Muruve DA. Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol. 2008 Mar; 82(6):2727-40.
    View in: PubMed
    Score: 0.004
  149. Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007 Dec 01; 179(11):7860-7.
    View in: PubMed
    Score: 0.004
  150. Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J Immunol. 2007 Sep 15; 179(6):4101-9.
    View in: PubMed
    Score: 0.004
  151. Lyubchenko T, Dal Porto JM, Holers VM, Cambier JC. Cutting edge: Complement (C3d)-linked antigens break B cell anergy. J Immunol. 2007 Sep 01; 179(5):2695-9.
    View in: PubMed
    Score: 0.004
  152. Lenderink AM, Liegel K, Ljubanovic D, Coleman KE, Gilkeson GS, Holers VM, Thurman JM. The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am J Physiol Renal Physiol. 2007 Aug; 293(2):F555-64.
    View in: PubMed
    Score: 0.004
  153. Mihai S, Chiriac MT, Takahashi K, Thurman JM, Holers VM, Zillikens D, Botto M, Sitaru C. The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J Immunol. 2007 May 15; 178(10):6514-21.
    View in: PubMed
    Score: 0.004
  154. Leinhase I, Rozanski M, Harhausen D, Thurman JM, Schmidt OI, Hossini AM, Taha ME, Rittirsch D, Ward PA, Holers VM, Ertel W, Stahel PF. Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. J Neuroinflammation. 2007 May 02; 4:13.
    View in: PubMed
    Score: 0.004
  155. Twohig J, Kulik L, Haluszczak C, Reuter J, Rossbach A, Bull M, Holers VM, Marchbank KJ. Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21) transgenic mice is partially recovered in the absence of C3. Mol Immunol. 2007 Jul; 44(13):3434-44.
    View in: PubMed
    Score: 0.004
  156. Schepers A, de Vries MR, van Leuven CJ, Grimbergen JM, Holers VM, Daha MR, van Bockel JH, Quax PH. Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice. Circulation. 2006 Dec 19; 114(25):2831-8.
    View in: PubMed
    Score: 0.004
  157. Thorgersen EB, Ghebremariam YT, Thurman JM, Fung M, Nielsen EW, Holers VM, Kotwal GJ, Mollnes TE. Candidate inhibitors of porcine complement. Mol Immunol. 2007 Mar; 44(8):1827-34.
    View in: PubMed
    Score: 0.004
  158. Szakonyi G, Klein MG, Hannan JP, Young KA, Ma RZ, Asokan R, Holers VM, Chen XS. Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol. 2006 Nov; 13(11):996-1001.
    View in: PubMed
    Score: 0.004
  159. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006 Sep 04; 203(9):2165-75.
    View in: PubMed
    Score: 0.003
  160. Gilbert HE, Asokan R, Holers VM, Perkins SJ. The 15 SCR flexible extracellular domains of human complement receptor type 2 can mediate multiple ligand and antigen interactions. J Mol Biol. 2006 Oct 06; 362(5):1132-47.
    View in: PubMed
    Score: 0.003
  161. Leinhase I, Holers VM, Thurman JM, Harhausen D, Schmidt OI, Pietzcker M, Taha ME, Rittirsch D, Huber-Lang M, Smith WR, Ward PA, Stahel PF. Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation. BMC Neurosci. 2006 Jul 14; 7:55.
    View in: PubMed
    Score: 0.003
  162. Taube C, Thurman JM, Takeda K, Joetham A, Miyahara N, Carroll MC, Dakhama A, Giclas PC, Holers VM, Gelfand EW. Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc Natl Acad Sci U S A. 2006 May 23; 103(21):8084-9.
    View in: PubMed
    Score: 0.003
  163. Leinhase I, Schmidt OI, Thurman JM, Hossini AM, Rozanski M, Taha ME, Scheffler A, John T, Smith WR, Holers VM, Stahel PF. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp Neurol. 2006 Jun; 199(2):454-64.
    View in: PubMed
    Score: 0.003
  164. Gilbert HE, Aslam M, Guthridge JM, Holers VM, Perkins SJ. Extended flexible linker structures in the complement chimaeric conjugate CR2-Ig by scattering, analytical ultracentrifugation and constrained modelling: implications for function and therapy. J Mol Biol. 2006 Feb 17; 356(2):397-412.
    View in: PubMed
    Score: 0.003
  165. Holers VM, Kotzin BL. Human peripheral blood monocytes display surface antigens recognized by monoclonal antinuclear antibodies. J Clin Invest. 1985 Sep; 76(3):991-8.
    View in: PubMed
    Score: 0.003
  166. Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005 Sep; 115(9):2444-53.
    View in: PubMed
    Score: 0.003
  167. Birrell L, Kulik L, Morgan BP, Holers VM, Marchbank KJ. B cells from mice prematurely expressing human complement receptor type 2 are unresponsive to T-dependent antigens. J Immunol. 2005 Jun 01; 174(11):6974-82.
    View in: PubMed
    Score: 0.003
  168. Li S, Boackle SA, Holers VM, Lambris JD, Blatteis CM. Complement component c5a is integral to the febrile response of mice to lipopolysaccharide. Neuroimmunomodulation. 2005; 12(2):67-80.
    View in: PubMed
    Score: 0.003
  169. Fleming SD, Egan RP, Chai C, Girardi G, Holers VM, Salmon J, Monestier M, Tsokos GC. Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol. 2004 Dec 01; 173(11):7055-61.
    View in: PubMed
    Score: 0.003
  170. Ohta R, Kondor N, Dohi N, Tomlinson S, Imai M, Holers VM, Okada H, Okada N. Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo. J Immunol. 2004 Jul 01; 173(1):205-13.
    View in: PubMed
    Score: 0.003
  171. M?hlfeld AS, Segerer S, Hudkins K, Farr AG, Bao L, Kraus D, Holers VM, Quigg RJ, Alpers CE. Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. Kidney Int. 2004 Apr; 65(4):1214-23.
    View in: PubMed
    Score: 0.003
  172. Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int. 2004 Jan; 65(1):129-38.
    View in: PubMed
    Score: 0.003
  173. Park JW, Taube C, Joetham A, Takeda K, Kodama T, Dakhama A, McConville G, Allen CB, Sfyroera G, Shultz LD, Lambris JD, Giclas PC, Holers VM, Gelfand EW. Complement activation is critical to airway hyperresponsiveness after acute ozone exposure. Am J Respir Crit Care Med. 2004 Mar 15; 169(6):726-32.
    View in: PubMed
    Score: 0.003
  174. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003 Dec; 112(11):1644-54.
    View in: PubMed
    Score: 0.003
  175. Alexander JJ, Bao L, Jacob A, Kraus DM, Holers VM, Quigg RJ. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim Biophys Acta. 2003 Nov 20; 1639(3):169-76.
    View in: PubMed
    Score: 0.003
  176. Bao L, Zhou J, Holers VM, Quigg RJ. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation. J Am Soc Nephrol. 2003 Oct; 14(10):2516-25.
    View in: PubMed
    Score: 0.003
  177. Taube C, Rha YH, Takeda K, Park JW, Joetham A, Balhorn A, Dakhama A, Giclas PC, Holers VM, Gelfand EW. Inhibition of complement activation decreases airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med. 2003 Dec 01; 168(11):1333-41.
    View in: PubMed
    Score: 0.003
  178. Banda NK, Kraus DM, Muggli M, Bendele A, Holers VM, Arend WP. Prevention of collagen-induced arthritis in mice transgenic for the complement inhibitor complement receptor 1-related gene/protein y. J Immunol. 2003 Aug 15; 171(4):2109-15.
    View in: PubMed
    Score: 0.003
  179. Aslam M, Guthridge JM, Hack BK, Quigg RJ, Holers VM, Perkins SJ. The extended multidomain solution structures of the complement protein Crry and its chimeric conjugate Crry-Ig by scattering, analytical ultracentrifugation and constrained modelling: implications for function and therapy. J Mol Biol. 2003 Jun 06; 329(3):525-50.
    View in: PubMed
    Score: 0.003
  180. Song H, He C, Knaak C, Guthridge JM, Holers VM, Tomlinson S. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest. 2003 Jun; 111(12):1875-85.
    View in: PubMed
    Score: 0.003
  181. Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, Quigg RJ. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol. 2003 Mar; 14(3):670-9.
    View in: PubMed
    Score: 0.003
  182. Banda NK, Kraus D, Vondracek A, Huynh LH, Bendele A, Holers VM, Arend WP. Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum. 2002 Nov; 46(11):3065-75.
    View in: PubMed
    Score: 0.003
  183. Perkins SJ, Gilbert HE, Aslam M, Hannan J, Holers VM, Goodship TH. Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation. Biochem Soc Trans. 2002 Nov; 30(Pt 6):996-1001.
    View in: PubMed
    Score: 0.003
  184. Li S, Holers VM, Boackle SA, Blatteis CM. Modulation of mouse endotoxic fever by complement. Infect Immun. 2002 May; 70(5):2519-25.
    View in: PubMed
    Score: 0.003
  185. Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol. 2002 Apr 01; 168(7):3601-7.
    View in: PubMed
    Score: 0.003
  186. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, Takahashi K, Holers VM, Walport M, Gerard C, Ezekowitz A, Carroll MC, Brenner M, Weissleder R, Verbeek JS, Duchatelle V, Degott C, Benoist C, Mathis D. Arthritis critically dependent on innate immune system players. Immunity. 2002 Feb; 16(2):157-68.
    View in: PubMed
    Score: 0.003
  187. Rehrig S, Fleming SD, Anderson J, Guthridge JM, Rakstang J, McQueen CE, Holers VM, Tsokos GC, Shea-Donohue T. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J Immunol. 2001 Nov 15; 167(10):5921-7.
    View in: PubMed
    Score: 0.003
  188. Boackle SA, Holers VM, Chen X, Szakonyi G, Karp DR, Wakeland EK, Morel L. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity. 2001 Nov; 15(5):775-85.
    View in: PubMed
    Score: 0.003
  189. Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T, Fairweather D, Holers VM, Rose NR. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol. 2001 Aug; 2(8):739-45.
    View in: PubMed
    Score: 0.002
  190. Park P, Haas M, Cunningham PN, Alexander JJ, Bao L, Guthridge JM, Kraus DM, Holers VM, Quigg RJ. Inhibiting the complement system does not reduce injury in renal ischemia reperfusion. J Am Soc Nephrol. 2001 Jul; 12(7):1383-1390.
    View in: PubMed
    Score: 0.002
  191. Springall T, Sheerin NS, Abe K, Holers VM, Wan H, Sacks SH. Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli. Nat Med. 2001 Jul; 7(7):801-6.
    View in: PubMed
    Score: 0.002
  192. Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol. 2001 May 15; 166(10):6444-51.
    View in: PubMed
    Score: 0.002
  193. Schiller B, Cunningham PN, Alexander JJ, Bao L, Holers VM, Quigg RJ. Expression of a soluble complement inhibitor protects transgenic mice from antibody-induced acute renal failure. J Am Soc Nephrol. 2001 Jan; 12(1):71-79.
    View in: PubMed
    Score: 0.002
  194. Cunningham PN, Holers VM, Alexander JJ, Guthridge JM, Carroll MC, Quigg RJ. Complement is activated in kidney by endotoxin but does not cause the ensuing acute renal failure. Kidney Int. 2000 Oct; 58(4):1580-7.
    View in: PubMed
    Score: 0.002
  195. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science. 2000 Jan 21; 287(5452):498-501.
    View in: PubMed
    Score: 0.002
  196. Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol. 2000 Jan 15; 164(2):786-94.
    View in: PubMed
    Score: 0.002
  197. Davoust N, Nataf S, Holers VM, Barnum SR. Expression of the murine complement regulatory protein crry by glial cells and neurons. Glia. 1999 Aug; 27(2):162-70.
    View in: PubMed
    Score: 0.002
  198. Nardin A, Schlimgen R, Holers VM, Taylor RP. A prototype pathogen bound ex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model. Eur J Immunol. 1999 05; 29(5):1581-6.
    View in: PubMed
    Score: 0.002
  199. Alexander JJ, Lim A, He C, MacDonald RL, Holers VM, Quigg RJ. Renal, central nervous system and pancreatic overexpression of recombinant soluble Crry in transgenic mice. A novel means of protection from complement-mediated injury. Immunopharmacology. 1999 May; 42(1-3):245-54.
    View in: PubMed
    Score: 0.002
  200. Fang Y, Xu C, Fu YX, Holers VM, Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol. 1998 Jun 01; 160(11):5273-9.
    View in: PubMed
    Score: 0.002
  201. Kearns-Jonker M, Monell-Torrens E, Abbasi F, Holers VM, Notkins AL, Sigounas G. EBV binds to lymphocytes of transgenic mice that express the human CR2 gene. Virus Res. 1997 Jul; 50(1):85-94.
    View in: PubMed
    Score: 0.002
  202. Kawamoto Y, Kojima K, Hitsumoto Y, Okada H, Holers VM, Miyama A. The serum resistance of malaria-infected erythrocytes. Immunology. 1997 May; 91(1):7-12.
    View in: PubMed
    Score: 0.002
  203. Alexander JJ, He C, Adler S, Holers VM, Quigg RJ. Characterization of C3 receptors on cultured rat glomerular endothelial cells. Kidney Int. 1997 Apr; 51(4):1124-32.
    View in: PubMed
    Score: 0.002
  204. Sawant-Mane S, Piddlesden SJ, Morgan BP, Holers VM, Koski CL. CD59 homologue regulates complement-dependent cytolysis of rat Schwann cells. J Neuroimmunol. 1996 Sep; 69(1-2):63-71.
    View in: PubMed
    Score: 0.002
  205. Rogers CA, Gasque P, Piddlesden SJ, Okada N, Holers VM, Morgan BP. Expression and function of membrane regulators of complement on rat astrocytes in culture. Immunology. 1996 May; 88(1):153-61.
    View in: PubMed
    Score: 0.002
  206. Molina H, Holers VM, Li B, Fung Y, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Chaplin DD. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci U S A. 1996 Apr 16; 93(8):3357-61.
    View in: PubMed
    Score: 0.002
  207. Quigg RJ, Morgan BP, Holers VM, Adler S, Sneed AE, Lo CF. Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Int. 1995 Aug; 48(2):412-21.
    View in: PubMed
    Score: 0.002
  208. Dunster LM, Schneider-Schaulies J, Dehoff MH, Holers VM, Schwartz-Albiez R, ter Meulen V. Moesin, and not the murine functional homologue (Crry/p65) of human membrane cofactor protein (CD46), is involved in the entry of measles virus (strain Edmonston) into susceptible murine cell lines. J Gen Virol. 1995 Aug; 76 ( Pt 8):2085-9.
    View in: PubMed
    Score: 0.002
  209. Shima M, Teitelbaum SL, Holers VM, Ruzicka C, Osmack P, Ross FP. Macrophage-colony-stimulating factor regulates expression of the integrins alpha 4 beta 1 and alpha 5 beta 1 by murine bone marrow macrophages. Proc Natl Acad Sci U S A. 1995 May 23; 92(11):5179-83.
    View in: PubMed
    Score: 0.002
  210. Quigg RJ, Holers VM, Morgan BP, Sneed AE. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol. 1995 Apr 01; 154(7):3437-43.
    View in: PubMed
    Score: 0.002
  211. Carel JC, Holers VM, Chick WL, Littman D, Lacy PE. Expression of functional human Epstein-Barr virus/C3d receptor ([CR2] CD21) on insulinoma cell line. Induction of tumor rejection but not diabetes in syngeneic rats. Diabetes. 1991 Jul; 40(7):809-14.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)